Symbols / AVDL
AVDL Chart
About
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.12B |
| Enterprise Value | 2.06B | Income | -278.00K | Sales | 248.52M |
| Book/sh | 1.01 | Cash/sh | 0.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 188 | IPO | Jun 07, 1996 |
| P/E | inf | Forward P/E | 27.74 | PEG | — |
| P/S | 8.55 | P/B | 21.43 | P/C | — |
| EV/EBITDA | 762.91 | EV/Sales | 8.29 | Quick Ratio | 2.15 |
| Current Ratio | 2.76 | Debt/Eq | 38.05 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | 0.78 | EPS Growth | — |
| Revenue Growth | 54.90% | Earnings | 2026-03-02 | ROA | -0.34% |
| ROE | -0.32% | ROIC | — | Gross Margin | 94.91% |
| Oper. Margin | 2.50% | Profit Margin | -0.11% | Shs Outstand | 98.15M |
| Shs Float | 91.56M | Short Float | 2.38% | Short Ratio | 1.60 |
| Short Interest | — | 52W High | 23.57 | 52W Low | 6.38 |
| Beta | — | Avg Volume | 2.18M | Volume | 35.02M |
| Target Price | $20.71 | Recom | Hold | Prev Close | $21.64 |
| Price | $21.64 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.71
Mean price target
2. Current target
$21.64
Latest analyst target
3. DCF / Fair value
$0.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$21.64
Low
$18.50
High
$23.00
Mean
$20.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-20 | main | Wells Fargo | Equal-Weight → Equal-Weight | $23 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $20 |
| 2025-10-28 | down | UBS | Buy → Neutral | $20 |
| 2025-10-23 | down | Leerink Partners | Outperform → Market Perform | $19 |
| 2025-10-23 | down | HC Wainwright & Co. | Buy → Neutral | $20 |
| 2025-10-22 | down | Jefferies | Buy → Hold | $20 |
| 2025-10-22 | down | Needham | Buy → Hold | — |
| 2025-09-05 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-09-03 | init | Wells Fargo | — → Equal-Weight | $16 |
| 2025-08-21 | main | UBS | Buy → Buy | $20 |
| 2025-08-08 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-05-08 | reit | Needham | Buy → Buy | $19 |
| 2025-04-09 | reit | Needham | Buy → Buy | $19 |
| 2025-03-04 | reit | Needham | Buy → Buy | $19 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-03-03 | reit | Needham | Buy → Buy | $19 |
| 2025-02-11 | init | Deutsche Bank | — → Buy | $12 |
| 2025-01-13 | main | UBS | Buy → Buy | $14 |
| 2025-01-10 | main | Piper Sandler | Overweight → Overweight | $13 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- Avadel Pharmaceuticals plc (AVDL) Stock Analysis: Navigating a 54.9% Revenue Growth Amidst Analyst Caution - DirectorsTalk Interviews Fri, 20 Feb 2026 20
- Avadel (AVDL) Gets 26% Boost on Takeover Bid - Yahoo Finance Sun, 16 Nov 2025 08
- Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan Mon, 12 Jan 2026 08
- AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to Shareholders - Business Wire Wed, 22 Oct 2025 07
- Analysts Are Split On This 'Very Confusing' $2.1 Billion Buyout - Investor's Business Daily Wed, 22 Oct 2025 07
- Avadel stock soars after receiving $23 per share acquisition offer - Investing.com Fri, 14 Nov 2025 08
- Stocks making big premarket moves: WBD, CDTX, AVDL and more - CNBC Fri, 14 Nov 2025 08
- Avadel (AVDL) stock: new SEC filing as shares stay suspended after $21 Alkermes buyout - Bez Kabli Wed, 18 Feb 2026 15
- Avadel Stock: Mispriced Leader In Once-Nightly Sleep Therapies (NASDAQ:AVDL) - Seeking Alpha ue, 30 Sep 2025 07
- US Market Recap: Is AVDL stock ready for breakout - July 2025 Selloffs & Capital Protection Trade Alerts - mfd.ru Sat, 21 Feb 2026 16
- Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge - Yahoo Finance Sun, 30 Nov 2025 08
- Avadel (NASDAQ: AVDL) receives $23/share Lundbeck proposal, vs $20 Alkermes deal - Stock Titan Fri, 14 Nov 2025 08
- Avadel (AVDL) stock is frozen near $21.64 — here’s what the latest filing says about the $21 cash-out - Bez Kabli hu, 19 Feb 2026 13
- Avadel climbs as Lundbeck outbids Alkermes in latest bidding war - Seeking Alpha Fri, 14 Nov 2025 08
- A Fresh Look at Avadel Pharmaceuticals (AVDL) Valuation After Share Price Rally - Yahoo Finance Sat, 15 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 67025 | — | — | Stock Gift at price 0.00 per share. | MCCAMISH MARK ANTHONY | Director | — | 2026-02-04 00:00:00 | I |
| 1 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | THORNTON PETER J | Director | — | 2025-07-29 00:00:00 | D |
| 2 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCAMISH MARK ANTHONY | Director | — | 2025-07-29 00:00:00 | D |
| 3 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | ENDE ERIC J | Director | — | 2025-07-29 00:00:00 | D |
| 4 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | GLASS GEOFFREY MICHAEL | Director | — | 2025-07-29 00:00:00 | D |
| 5 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | AMIN NASEEM M.D. | Director | — | 2025-07-29 00:00:00 | D |
| 6 | 11000 | — | — | Stock Award(Grant) at price 0.00 per share. | PALCZUK LINDA S | Director | — | 2025-07-29 00:00:00 | D |
| 7 | 12600 | — | — | Stock Award(Grant) at price 0.00 per share. | MCHUGH THOMAS S | Chief Financial Officer | — | 2025-03-05 00:00:00 | D |
| 8 | 52000 | — | — | Stock Award(Grant) at price 0.00 per share. | DIVIS GREGORY J. JR. | Chief Executive Officer | — | 2025-03-05 00:00:00 | D |
| 9 | 14700 | — | — | Stock Award(Grant) at price 0.00 per share. | SEURER JERAD G. | General Counsel | — | 2025-03-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 20.89K | -40.64K | -815.01K | 406.84K |
| TaxRateForCalcs | 0.01 | 0.00 | 0.21 | 0.17 |
| NormalizedEBITDA | -39.72M | -136.08M | -93.72M | -84.78M |
| TotalUnusualItems | 4.15M | -13.04M | -3.88M | 2.40M |
| TotalUnusualItemsExcludingGoodwill | 4.15M | -13.04M | -3.88M | 2.40M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -48.83M | -160.28M | -137.46M | -77.33M |
| ReconciledDepreciation | 2.68M | 1.77M | 1.49M | 815.00K |
| ReconciledCostOfRevenue | 15.28M | 846.00K | 0.00 | 0.00 |
| EBITDA | -35.57M | -149.12M | -97.60M | -82.39M |
| EBIT | -38.25M | -150.89M | -99.10M | -83.20M |
| NetInterestIncome | -10.83M | -9.89M | -12.34M | -9.94M |
| InterestExpense | 10.83M | 9.89M | 12.34M | 9.94M |
| NormalizedIncome | -52.96M | -147.27M | -134.40M | -79.32M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -48.83M | -160.28M | -137.46M | -77.33M |
| TotalExpenses | 211.52M | 165.81M | 95.22M | 85.60M |
| TotalOperatingIncomeAsReported | -42.40M | -137.85M | -98.56M | -85.55M |
| DilutedAverageShares | 95.14M | 80.17M | 60.09M | 58.53M |
| BasicAverageShares | 95.14M | 80.17M | 60.09M | 58.53M |
| DilutedEPS | -0.51 | -2.00 | -2.29 | -1.32 |
| BasicEPS | -0.51 | -2.00 | -2.29 | -1.32 |
| DilutedNIAvailtoComStockholders | -48.83M | -160.28M | -137.46M | -77.33M |
| NetIncomeCommonStockholders | -48.83M | -160.28M | -137.46M | -77.33M |
| NetIncome | -48.83M | -160.28M | -137.46M | -77.33M |
| NetIncomeIncludingNoncontrollingInterests | -48.83M | -160.28M | -137.46M | -77.33M |
| NetIncomeContinuousOperations | -48.83M | -160.28M | -137.46M | -77.33M |
| TaxProvision | -247.00K | -501.00K | 26.02M | -15.82M |
| PretaxIncome | -49.08M | -160.78M | -111.44M | -93.14M |
| OtherIncomeExpense | 4.15M | -13.04M | -3.88M | 2.40M |
| OtherNonOperatingIncomeExpenses | 217.00K | |||
| SpecialIncomeCharges | 0.00 | -13.13M | -3.35M | 53.00K |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | 13.13M | |||
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | 3.35M | -53.00K |
| GainOnSaleOfSecurity | 4.15M | 87.00K | -536.00K | 2.34M |
| NetNonOperatingInterestIncomeExpense | -10.83M | -9.89M | -12.34M | -9.94M |
| InterestExpenseNonOperating | 10.83M | 9.89M | 12.34M | 9.94M |
| OperatingIncome | -42.40M | -137.85M | -95.22M | -85.60M |
| OperatingExpense | 196.24M | 164.97M | 95.22M | 85.60M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | |||
| DepreciationAndAmortizationInIncomeStatement | 0.00 | |||
| Amortization | 0.00 | |||
| AmortizationOfIntangiblesIncomeStatement | 0.00 | |||
| ResearchAndDevelopment | 15.20M | 13.26M | 20.70M | 17.10M |
| SellingGeneralAndAdministration | 181.04M | 151.71M | 74.52M | 68.50M |
| GrossProfit | 153.84M | 27.12M | 0.00 | 0.00 |
| CostOfRevenue | 15.28M | 846.00K | 0.00 | 0.00 |
| TotalRevenue | 169.12M | 27.96M | 0.00 | 0.00 |
| OperatingRevenue | 169.12M | 27.96M | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 96.52M | 89.83M | 62.88M | 58.62M |
| ShareIssued | 96.52M | 89.83M | 62.88M | 58.62M |
| NetDebt | 55.30M | 91.69M | ||
| TotalDebt | 1.70M | 2.62M | 131.02M | 145.00M |
| TangibleBookValue | 57.01M | 70.85M | -37.99M | 61.40M |
| InvestedCapital | 73.85M | 87.69M | 108.13M | 220.64M |
| WorkingCapital | 85.37M | 97.35M | 45.05M | 171.49M |
| NetTangibleAssets | 57.01M | 70.90M | -37.98M | 61.41M |
| CapitalLeaseObligations | 1.70M | 2.62M | 1.74M | 2.61M |
| CommonStockEquity | 73.85M | 87.69M | -21.15M | 78.24M |
| PreferredStockEquity | 52.00K | 5.00K | 5.00K | |
| TotalCapitalization | 73.85M | 87.74M | 70.47M | 220.64M |
| TotalEquityGrossMinorityInterest | 73.85M | 87.74M | -21.14M | 78.24M |
| StockholdersEquity | 73.85M | 87.74M | -21.14M | 78.24M |
| GainsLossesNotAffectingRetainedEarnings | -24.58M | -23.17M | -26.34M | -23.94M |
| OtherEquityAdjustments | -24.58M | -23.17M | -26.34M | -23.94M |
| RetainedEarnings | -794.33M | -745.50M | -585.22M | -447.76M |
| AdditionalPaidInCapital | 891.79M | 855.45M | 589.78M | 549.35M |
| CapitalStock | 965.00K | 950.00K | 633.00K | 591.00K |
| CommonStock | 965.00K | 898.00K | 628.00K | 586.00K |
| PreferredStock | 0.00 | 52.00K | 5.00K | 5.00K |
| TotalLiabilitiesNetMinorityInterest | 90.39M | 76.96M | 153.93M | 169.02M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 41.55M | 40.10M | 98.14M | 148.02M |
| OtherNonCurrentLiabilities | 35.28M | 33.01M | 497.00K | 3.92M |
| TradeandOtherPayablesNonCurrent | 5.15M | 5.41M | 5.25M | |
| LongTermDebtAndCapitalLeaseObligation | 1.12M | 1.69M | 92.39M | 144.10M |
| LongTermCapitalLeaseObligation | 1.12M | 1.69M | 780.00K | 1.71M |
| LongTermDebt | 91.61M | 142.40M | ||
| CurrentLiabilities | 48.83M | 36.85M | 55.79M | 21.00M |
| OtherCurrentLiabilities | 273.00K | 261.00K | 292.00K | 350.00K |
| CurrentDebtAndCapitalLeaseObligation | 582.00K | 934.00K | 38.63M | 900.00K |
| CurrentCapitalLeaseObligation | 582.00K | 934.00K | 960.00K | 900.00K |
| CurrentDebt | 37.67M | |||
| OtherCurrentBorrowings | 37.67M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.51M | 7.49M | 1.61M | 3.17M |
| CurrentProvisions | 14.22M | 4.04M | 217.00K | |
| PayablesAndAccruedExpenses | 27.25M | 24.12M | 15.26M | 16.58M |
| CurrentAccruedExpenses | 18.03M | 11.96M | 7.37M | 8.90M |
| InterestPayable | 0.00 | 1.65M | 4.92M | |
| Payables | 9.22M | 12.16M | 7.89M | 7.68M |
| OtherPayable | 1.89M | 730.00K | ||
| AccountsPayable | 7.33M | 11.43M | 7.89M | 7.68M |
| TotalAssets | 164.24M | 164.70M | 132.78M | 247.26M |
| TotalNonCurrentAssets | 30.03M | 30.50M | 31.94M | 54.77M |
| OtherNonCurrentAssets | 337.00K | 579.00K | 636.00K | 1.10M |
| NonCurrentDeferredAssets | 0.00 | 24.13M | ||
| NonCurrentDeferredTaxesAssets | 0.00 | 24.13M | ||
| NonCurrentAccountsReceivable | 332.00K | 1.23M | 1.23M | |
| GoodwillAndOtherIntangibleAssets | 16.84M | 16.84M | 16.84M | 16.84M |
| Goodwill | 16.84M | 16.84M | 16.84M | 16.84M |
| NetPPE | 12.86M | 13.08M | 13.24M | 11.49M |
| AccumulatedDepreciation | -1.01M | -881.00K | -627.00K | -465.00K |
| GrossPPE | 13.87M | 13.96M | 13.87M | 11.95M |
| OtherProperties | 12.40M | 12.50M | 12.40M | 11.20M |
| MachineryFurnitureEquipment | 1.47M | 1.47M | 1.47M | 750.00K |
| CurrentAssets | 134.21M | 134.20M | 100.84M | 192.49M |
| OtherCurrentAssets | 882.00K | 2.23M | 573.00K | 550.00K |
| PrepaidAssets | 5.15M | 4.37M | 1.52M | 3.18M |
| Inventory | 20.30M | 10.38M | 0.00 | |
| FinishedGoods | 10.14M | 3.05M | ||
| WorkInProcess | 4.96M | 2.04M | ||
| RawMaterials | 5.20M | 5.29M | ||
| Receivables | 34.10M | 12.10M | 2.25M | 31.54M |
| TaxesReceivable | 1.32M | 2.25M | 31.54M | |
| AccountsReceivable | 34.10M | 12.10M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 73.78M | 105.11M | 96.50M | 157.22M |
| OtherShortTermInvestments | 22.41M | 73.94M | 22.52M | 106.51M |
| CashAndCashEquivalents | 51.37M | 31.17M | 73.98M | 50.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -46.91M | -128.51M | -71.02M | -77.34M |
| RepaymentOfDebt | 0.00 | -38.66M | -8.65M | 0.00 |
| IssuanceOfCapitalStock | 9.25M | 146.06M | 25.32M | 0.00 |
| CapitalExpenditure | -716.00K | -26.00K | ||
| InterestPaidSupplementalData | 7.18M | 5.25M | 9.66M | 6.47M |
| IncomeTaxPaidSupplementalData | 0.00 | 76.00K | ||
| EndCashPosition | 51.37M | 31.17M | 73.98M | 50.71M |
| BeginningCashPosition | 31.17M | 73.98M | 50.71M | 71.72M |
| EffectOfExchangeRateChanges | -639.00K | 455.00K | -664.00K | -896.00K |
| ChangesInCash | 20.84M | -43.27M | 23.94M | -20.12M |
| FinancingCashFlow | 15.97M | 135.34M | 14.54M | 263.00K |
| CashFlowFromContinuingFinancingActivities | 15.97M | 135.34M | 14.54M | 263.00K |
| NetOtherFinancingCharges | 25.64M | -4.80M | ||
| ProceedsFromStockOptionExercised | 6.72M | 2.29M | 2.68M | 263.00K |
| NetCommonStockIssuance | 9.25M | 146.06M | 25.32M | 0.00 |
| CommonStockIssuance | 9.25M | 146.06M | 25.32M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -38.66M | -8.65M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -38.66M | -8.65M | 0.00 |
| LongTermDebtPayments | 0.00 | -38.66M | -8.65M | 0.00 |
| InvestingCashFlow | 51.78M | -50.09M | 79.70M | 56.93M |
| CashFlowFromContinuingInvestingActivities | 51.78M | -50.09M | 79.70M | 56.93M |
| NetInvestmentPurchaseAndSale | 51.78M | -50.09M | 80.41M | 40.45M |
| SaleOfInvestment | 327.78M | 187.14M | 83.83M | 102.22M |
| PurchaseOfInvestment | -276.00M | -237.23M | -3.41M | -61.77M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 16.50M | |
| SaleOfBusiness | 0.00 | 0.00 | 16.50M | |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -716.00K | -26.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | 0.00 | 0.00 | -716.00K | -26.00K |
| OperatingCashFlow | -46.91M | -128.51M | -70.30M | -77.31M |
| CashFlowFromContinuingOperatingActivities | -46.91M | -128.51M | -70.30M | -77.31M |
| ChangeInWorkingCapital | -20.32M | -3.00M | 24.54M | 3.69M |
| ChangeInOtherWorkingCapital | -1.85M | 2.35M | -3.53M | -3.79M |
| ChangeInPayablesAndAccruedExpense | 12.33M | 18.44M | -2.88M | 5.13M |
| ChangeInAccruedExpense | 16.42M | 16.89M | 227.00K | 895.00K |
| ChangeInPayable | -4.09M | 1.54M | -3.11M | 4.23M |
| ChangeInAccountPayable | -4.09M | 1.54M | -3.11M | 4.23M |
| ChangeInPrepaidAssets | 416.00K | -2.15M | 30.95M | -439.00K |
| ChangeInInventory | -9.22M | -9.53M | 0.00 | 0.00 |
| ChangeInReceivables | -21.99M | -12.10M | 0.00 | 2.80M |
| ChangesInAccountReceivables | -21.99M | -12.10M | 0.00 | 0.00 |
| OtherNonCashItems | -828.00K | 4.06M | 8.09M | 2.30M |
| StockBasedCompensation | 20.39M | 15.81M | 7.01M | 8.87M |
| DeferredTax | 0.00 | 0.00 | 26.02M | -15.67M |
| DeferredIncomeTax | 0.00 | 0.00 | 26.02M | -15.67M |
| DepreciationAmortizationDepletion | 2.68M | 1.77M | 1.49M | 815.00K |
| DepreciationAndAmortization | 2.68M | 1.77M | 1.49M | 815.00K |
| OperatingGainsLosses | 13.13M | |||
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -48.83M | -160.28M | -137.46M | -77.33M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AVDL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|